Five Prime Therapeutics starts dosing FPA144 in Phase 1 clinical trial
Designed to slow down tumor growth, the FPA144 prevents the binding of fibroblast growth factors to FGF receptor 2b (FGFR2b) and is being developed initially as a monotherapy
Designed to slow down tumor growth, the FPA144 prevents the binding of fibroblast growth factors to FGF receptor 2b (FGFR2b) and is being developed initially as a monotherapy
Under the deal, Pfizer will review medicines that are currently under development to find substances with a probable or high risk of abuse in sport. The company will
Reassuring Member States over safety of flu vaccine, the review conducted by the committee found that the vaccine was safe for administration in vaccination campaigns. The review follows
A novel screening approach has been developed by Monash University researchers, led by Professor David Jans in the Department of Biochemistry, to identify new classes of antiviral drugs.
In an emailed statement, a GSK spokesman was quoted by Reuters as saying: "This is a significant programme and will result in the loss of several hundred employees
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. With this approval, BLINCYTO becomes
The multi-year grants that worth about $3.5m will be used for the projects that focus on hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in high-risk
Due to its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for
Xyrem (sodium oxybate) oral solution, CIII, is indicated to treat cataplexy in narcolepsy and for the treatment of excessive daytime sleepiness (EDS) in narcolepsy. The drug is the
The company plans to follow up by submitting a briefing package on a later date in support of a pre-IND meeting to review the company’s proposed strategy and